---
title: "WUXI APPTEC once again clarifies: Never posed a national security risk, and does not engage in human genomics business."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/108099947.md"
description: "WUXI APPTEC has issued a clarification announcement, denying any national security risks and refuting the existence of any human genomics business. The company strongly opposes misleading allegations and preemptive actions taken without due process. WUXI APPTEC provides contract-based research, development, and manufacturing services, dedicated to advancing new drug development."
datetime: "2024-02-18T08:14:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/108099947.md)
  - [en](https://longbridge.com/en/news/108099947.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/108099947.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/108099947.md) | [繁體中文](https://longbridge.com/zh-HK/news/108099947.md)


# WUXI APPTEC once again clarifies: Never posed a national security risk, and does not engage in human genomics business.

Zhitong App news, WUXI APPTEC (603259.SH) issued a clarification announcement. The company noted that on February 12, 2024, some U.S. lawmakers wrote to the U.S. Departments of Commerce, Treasury, and Defense regarding the company. The company has always welcomed regulatory scrutiny in its industry and has successfully passed reviews by the U.S. government in the past. However, the company strongly opposes misleading allegations, inaccurate identifications, and prejudgment actions without due process against the company. The company firmly believes that it has not posed, does not pose, and will not pose a national security risk to the United States in the past, present, or future. Even if the U.S. government conducts another review of the company, the same conclusion will be reached.

The company also reiterated that it does not engage in human genomics business and its existing businesses do not collect human genomic data. The company provides contract-based research, development, and production services, empowering the global pharmaceutical and life sciences industries to drive new drug development and bring life-saving drugs to patients.

### Related Stocks

- [WuXi AppTec (603259.CN)](https://longbridge.com/en/quote/603259.CN.md)
- [WUXI APPTEC (02359.HK)](https://longbridge.com/en/quote/02359.HK.md)

## Related News & Research

- [How to approach the market during the "fog of war"](https://longbridge.com/en/news/281686621.md)
- [Baiyunshan Pharma Gets Approval for Carbocisteine Oral Solution's Registration in Macau](https://longbridge.com/en/news/281478355.md)
- [Baiyunshan Pharmaceutical Gets Nod for Marketing Transfer of Bone Health Drug](https://longbridge.com/en/news/281477935.md)
- [This bike rack pioneer is selling Bluetooth suction cups to stick bikes to your car](https://longbridge.com/en/news/281570168.md)
- [Americans Concerned New Medicare Advantage Coverage Limitation Is Too Vague](https://longbridge.com/en/news/281652061.md)